Premium
Safety and efficacy of telbivudine in late pregnancy to prevent mother‐to‐child transmission of hepatitis B virus: A multicenter prospective cohort study
Author(s) -
Hu Y.,
Xu C.,
Xu B.,
Hu L.,
Liu Q.,
Chen J.,
Liu J.,
Liu L.,
Yang J.,
Chen T.,
Wen J.,
Jiang N.,
Zhang Y.,
Cao M.,
Feng J.,
Lin X.,
Wang Z.,
Xu B.,
Zhou Y. H.
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12834
Subject(s) - telbivudine , medicine , hbeag , hepatitis b virus , prospective cohort study , pediatrics , hepatitis b , pregnancy , cohort , obstetrics , cohort study , transmission (telecommunications) , hbsag , lamivudine , immunology , virus , biology , genetics , electrical engineering , engineering
Summary Infection of hepatitis B virus ( HBV ) occurs in ~10% of infants of HBV ‐infected mothers with positive hepatitis B e antigen ( HB eAg) after immunoprophylaxis. We aimed to evaluate the safety and efficacy of telbivudine used during late pregnancy for preventing mother‐to‐child transmission of HBV . We conducted a multicenter prospective cohort study in 5 hospitals from 2012 to 2014, which enrolled HBV ‐infected singleton pregnant women with positive HB eAg. By their choice, women were divided into therapy (telbivudine 600 mg/day, from gestation 28‐32 weeks to 3‐4 weeks postpartum) and control (no antiviral agent) groups. Infants received passive‐active immunoprophylaxis and follow‐up at the age of 7‐14 months. Totally, 328 pregnant women were included: 149 in the telbivudine group and 179 in the control group. Baseline HBV DNA levels were similar in the 2 groups (7.43 vs 7.37 log 10 IU /mL, P = .711). At delivery, HBV DNA levels in the telbivudine and control groups were 3.80 and 7.26 log 10 IU /mL, respectively ( P < .0001). Of the infants, 128 (85.9%) in the telbivudine group and 156 (87.2%) in the control group were followed up. No infant in the telbivudine group had chronic infection, while 2 (1.28%) infants in the control group did ( P = .503). Three (2.34%) infants in the telbivudine group, but none in the control group, had severe congenital or developmental abnormalities ( P = .090). The data indicate that telbivudine may block perinatal HBV transmission. However, larger studies are required to clarify whether anti‐ HBV therapy in pregnancy is associated with severe adverse effects in the foetuses and infants.